Mens, Helene;
Fjordside, Lasse;
Gynthersen, Rosa;
Ørbaek, Mathilde;
Andersen, Åse Bengaard;
Andreasson, Ulf;
Blennow, Kaj;
... Lebech, Anne-Mette; + view all
(2023)
Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and not associated with persistent symptoms.
European Journal of Neurology
, 30
(5)
pp. 1371-1377.
10.1111/ene.15707.
Preview |
Text
Euro J of Neurology - 2023 - Mens - Plasma neurofilament light significantly decreases following treatment in Lyme.pdf - Accepted Version Download (737kB) | Preview |
Abstract
BACKGROUND: Currently there is an unmet need for a highly standardized blood biomarker test to monitor treatment response in Lyme neuroborreliosis (LNB). Differentiating between active or past infection is challenged by the relatively high frequency of persistent symptoms after the end of antibiotic treatment (estimated 15-20%), variable clinical course and the long-lasting B. burgdorferi antibodies. We therefore wanted to evaluate plasma NfL as a marker for disease activity in LNB. METHODS: Prospective included cohort of definite LNB (N=36) with blood samples and clinical evaluation including Glasgow Outcome Score (GOS) at treatment initiation, 3- and 6-months follow-up. Consecutive plasma was retrospectively analyzed for the content of NfL by Quanterix® kits (Simoa® NF-light Kit). RESULTS: pNfL significantly decreased between treatment initiation and 3-months follow-up (median 83 pg/ml vs median 14 pg/ml (25 pairs), p<0.0001). No significant change was observed between 3- and 6-months follow-up (median 14 pg/ml vs median 12 pg/ml (21 pairs), p=0.33). At treatment initiation 90% had pNfL above the age defined reference compared to only 23% and 7% respectively at 3- and 6-months follow-up. Decreases in pNfL were mirrored by increasing GOS. Reporting persistent symptoms at the 6 months follow-up was not associated with plasma NfL (relative change from reference or actual values) at baseline or at 6 months follow-up CONCLUSION: pNfL decreases following antibiotic treatment in LNB and is not associated with reporting persistent symptoms. We therefore speculate that it may prove useful as a treatment response biomarker in LNB.
| Type: | Article |
|---|---|
| Title: | Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and not associated with persistent symptoms |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/ene.15707 |
| Publisher version: | https://doi.org/10.1111/ene.15707 |
| Language: | English |
| Additional information: | Copyright © 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Lyme neuroborreliosis, Neurofilament Light chain, biomarker, neuroinflammation, persistent symptoms |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10164566 |
Archive Staff Only
 |
View Item |
